225Ac and 213Bi are considered as the favorable radionuclide pair for the next generation of Targeted Radionuclide Therapy.
State of the art radionuclides for research on cancer treatments are currently medium range beta emitters such as 177Lu. With the increase of specific activity, for example achieved by the development of n.c.a. 177Lu, therapeutic doses could be delivered not only to the primary tumor, but also to small metastases.
Nevertheless, micrometastases or single cell diseases like leukemia can still not be reached effectively.
For these kinds of cancers, alpha emitting radionuclides such as 213Bi or 225Ac would be the favorable choice. Due to the small penetration range of alpha particles in tissue and their high linear energy transfer (LET) they promise a superior ratio between penetration of cancer cells and protection of healthy tissue.
This product is for laboratory research purposes only